Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009-2013 | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
Almasi  EA, Stafford  RS, Kravitz  RL, Mansfield  PR.  What are the public health effects of direct-to-consumer drug advertising?  PLoS Med. 2006;3(3):e145.PubMedGoogle ScholarCrossref
2.
Brody  H, Light  DW.  The inverse benefit law: how drug marketing undermines patient safety and public health.  Am J Public Health. 2011;101(3):399-404.PubMedGoogle ScholarCrossref
3.
Daubresse  M, Hutfless  S, Kim  Y,  et al.  Effect of direct-to-consumer advertising on asthma medication sales and healthcare use.  Am J Respir Crit Care Med. 2015;192(1):40-46.PubMedGoogle ScholarCrossref
4.
Avery  RJ, Eisenberg  MD, Simon  KI.  The impact of direct-to-consumer television and magazine advertising on antidepressant use.  J Health Econ. 2012;31(5):705-718.PubMedGoogle ScholarCrossref
5.
Kim  Y, Kornfield  R, Shi  Y,  et al.  Effects of televised direct-to-consumer advertising for varenicline on prescription dispensing in the United States, 2006-2009.  Nicotine Tob Res. 2016;18(5):1180-1187.PubMedGoogle ScholarCrossref
6.
American Medical Association. AMA calls for ban on DTC ads of prescription drugs and medical devices [press release]. November 17, 2015. https://www.ama-assn.org/content/ama-calls-ban-direct-consumer-advertising-prescription-drugs-and-medical-devices. Accessed March 30, 2016.
7.
Handelsman  DJ.  Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse.  Med J Aust. 2013;199(8):548-551.PubMedGoogle ScholarCrossref
8.
Layton  JB, Li  D, Meier  CR,  et al.  Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011.  J Clin Endocrinol Metab. 2014;99(3):835-842.PubMedGoogle ScholarCrossref
9.
Bjerkeli  PJ, Mulinari  S, Merlo  J.  Testosterone prescribing in the population-a short social epidemiological analysis in Sweden.  Pharmacoepidemiol Drug Saf. 2016;25(1):11-15.PubMedGoogle ScholarCrossref
10.
Srinivas-Shankar  U, Roberts  SA, Connolly  MJ,  et al.  Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study.  J Clin Endocrinol Metab. 2010;95(2):639-650.PubMedGoogle ScholarCrossref
11.
Vigen  R, O’Donnell  CI, Barón  AE,  et al.  Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels.  JAMA. 2013;310(17):1829-1836.PubMedGoogle ScholarCrossref
12.
Wang  C, Cunningham  G, Dobs  A,  et al.  Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.  J Clin Endocrinol Metab. 2004;89(5):2085-2098.PubMedGoogle ScholarCrossref
13.
Onasanya  O, Iyer  G, Lucas  E, Lin  D, Singh  S, Alexander  GC.  Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews.  Lancet Diabetes Endocrinol. 2016;4(11):943-956.PubMedGoogle ScholarCrossref
14.
Basaria  S, Coviello  AD, Travison  TG,  et al.  Adverse events associated with testosterone administration.  N Engl J Med. 2010;363(2):109-122.PubMedGoogle ScholarCrossref
15.
Finkle  WD, Greenland  S, Ridgeway  GK,  et al.  Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men.  PLoS One. 2014;9(1):e85805.PubMedGoogle ScholarCrossref
16.
Szczypka  G, Emery  S, Wakefield  MA, Chaloupka  FJ. The Adaptation and Use of Nielsen Media Research Commercial Ratings Data to Measure Potential Exposure to Televised Smoking-Related Advertisements. May 2003. impacTEEN Research Paper Series No. 29. http://impacteen.uic.edu/generalarea_PDFs/Nielsenpaper_051403.pdf. Accessed February 21, 2017.
17.
Nielsen. TV ratings. http://www.nielsen.com/us/en/solutions/measurement/television.html. Accessed December 20, 2016.
18.
Kornfield  R, Alexander  GC, Qato  DM, Kim  Y, Hirsch  JD, Emery  SL.  Trends in exposure to televised prescription drug advertising, 2003-2011.  Am J Prev Med. 2015;48(5):575-579.PubMedGoogle ScholarCrossref
19.
Hansen  LG, Chang  S. White Paper: Health Research Data for the Real World: The MarketScan Databases. Ann Arbor, MI: Truven Health Analytics; 2012. http://truvenhealth.com/portals/0/assets/PH_11238_0612_TEMP_MarketScan_WP_FINAL.pdf. Accessed February 23, 2017.
20.
Liang  K-Y, Zeger  SL.  Longitudinal data analysis using generalized linear models.  Biometrika. 1986;73(1):13-22.Google ScholarCrossref
21.
US Food and Drug Administration. Testosterone gel safety concerns prompt FDA to require label changes, medication guide [press release]. May 7, 2009. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm149580.htm. Accessed December 25, 2016.
22.
Eli Lilly and Co. Axiron (testosterone) topical solution CIII now available in pharmacies [press release]. April 1, 2011. https://investor.lilly.com/releasedetail2.cfm?releaseid=561425. Accessed December 26, 2016.
23.
US Food and Drug Administration. Androgel (testosterone gel) 1.62%. November 17, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022309_androgel_toc.cfm. Accessed December 26, 2016.
24.
US Department of Health and Human Services. Analysis of databases from health care systems or large epidemiologic studies to evaluate safety of testosterone administration in older men (R01). https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-12-007.html. Accessed December 26, 2016.
25.
Altman  DG, Bland  JM.  Interaction revisited: the difference between two estimates.  BMJ. 2003;326(7382):219.PubMedGoogle ScholarCrossref
26.
Bhasin  S, Cunningham  GR, Hayes  FJ,  et al; Task Force, Endocrine Society.  Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.  J Clin Endocrinol Metab. 2010;95(6):2536-2559.PubMedGoogle ScholarCrossref
27.
McKinlay  JB, Trachtenberg  F, Marceau  LD, Katz  JN, Fischer  MA.  Effects of patient medication requests on physician prescribing behavior: results of a factorial experiment.  Med Care. 2014;52(4):294-299.PubMedGoogle ScholarCrossref
28.
Kravitz  RL, Epstein  RM, Feldman  MD,  et al.  Influence of patients’ requests for direct-to-consumer advertised antidepressants: a randomized controlled trial.  JAMA. 2005;293(16):1995-2002.PubMedGoogle ScholarCrossref
29.
Liu  Q, Gupta  S.  The impact of direct-to-consumer advertising of prescription drugs on physician visits and drug requests: empirical findings and public policy implications.  Int J Res Mark. 2011;28(3):205-217.Google ScholarCrossref
30.
US Food and Drug Administration.  Joint Meeting for Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management Advisory Committee (DSARM AC). College Park, MD: US Food and Drug Administration; 2014.
31.
Snyder  PJ, Bhasin  S, Cunningham  GR,  et al; Testosterone Trials Investigators.  Effects of testosterone treatment in older men.  N Engl J Med. 2016;374(7):611-624.PubMedGoogle ScholarCrossref
32.
Dijkstra  M, Buijtels  HEJJM, van Raaij  WF.  Separate and joint effects of medium type on consumer responses: a comparison of television, print, and the internet.  J Bus Res. 2005;58(3):377-386.Google ScholarCrossref
33.
FiercePharma. Top 10 drug advertising spends—Q1 2012. http://www.fiercepharma.com/special-report/top-10-drug-advertising-spends-q1-2012. Accessed August 19, 2016.
Original Investigation
March 21, 2017

Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009-2013

Author Affiliations
  • 1Department of Epidemiology, University of North Carolina at Chapel Hill
  • 2NORC at the University of Chicago, Chicago, Illinois
  • 3Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
  • 4Departments of Epidemiology and Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
JAMA. 2017;317(11):1159-1166. doi:10.1001/jama.2016.21041
Key Points

Question  Is there an association between televised direct-to-consumer testosterone advertising and testosterone testing and initiation in the United States?

Findings  In this ecological study of 75 US designated market areas, each exposure to a testosterone advertisement was associated with monthly relative increases in rates of new testosterone testing of 0.6%, new initiation of 0.7%, and initiation without a recent baseline test of 0.8%.

Meaning  Regional exposure to televised direct-to-consumer advertising was associated with greater testosterone testing, new initiation, and initiation without recent serum testosterone tests.

Abstract

Importance  Testosterone initiation increased substantially in the United States from 2000 to 2013, especially among men without clear indications. Direct-to-consumer advertising (DTCA) also increased during this time.

Objective  To investigate associations between televised DTCA and testosterone testing and initiation in the United States.

Design, Setting, and Population  Ecologic study conducted in designated market areas (DMAs) in the United States. Monthly testosterone advertising ratings were linked to DMA-level testosterone use data from 2009-2013 derived from commercial insurance claims. Associations between DTCA and testosterone testing, initiation, and initiation without recent baseline tests were estimated using Poisson generalized estimating equations.

Exposures  Monthly Nielsen ratings for testosterone DTCA in the 75 largest DMAs.

Main Outcomes and Measures  (1) Rates of new serum testosterone testing; (2) rates of testosterone initiation (in-office injection, surgical implant, or pharmacy dispensing) for all testosterone products combined and for specific brands; and (3) rates of testosterone initiation without recent serum testosterone testing.

Results  Of 17 228 599 commercially insured men in the 75 DMAs, 1 007 990 (mean age, 49.6 [SD, 11.5] years) had new serum testosterone tests and 283 317 (mean age, 51.8 [SD, 11.3] years) initiated testosterone treatment. Advertising intensity varied by geographic region and time, with the highest intensity seen in the southeastern United States and with months ranging from no ad exposures to a mean of 13.6 exposures per household. Nonbranded advertisements were common prior to 2012, with branded advertisements becoming more common during and after 2012. Each household advertisement exposure was associated with a monthly increase in rates of new testosterone testing (rate ratio [RR], 1.006; 95% CI, 1.004-1.008), initiation (RR, 1.007; 95% CI, 1.004-1.010), and initiation without a recent test (RR, 1.008; 95% CI, 1.002-1.013). Mean absolute rate increases were 0.14 tests (95% CI, 0.09-0.19), 0.05 new initiations (95% CI, 0.03-0.08), and 0.02 initiations without a recent test (95% CI, 0.01-0.03) per 10 000 men for each monthly ad exposure over the entire period.

Conclusions and Relevance  Among US men residing in the 75 designated market areas, regional exposure to televised direct-to-consumer advertising was associated with greater testosterone testing, new initiation, and initiation without recent testing.

×